Novo Biosciences Receives Federal Grant to Advance Potential Heart Drug

Novo Biosciences Receives Federal Grant to Advance Potential Heart Drug
Novo Biosciences Inc. has announced that it has received a two-year, $1.5 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of MSI-1436 as a potential regenerative medicine therapy for the treatment of patients who have suffered an acute heart attack.
3.4
Summary rating from 0 user's marks. You can set own marks for this article - just click on stars above and press "Accept".
0

Novo Biosciences Inc. has announced that it has received a two-year, $1.5 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of MSI-1436 as a potential regenerative medicine therapy for the treatment of patients who have suffered an acute heart attack.